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H5N1bilitating neurological disorder that affects 1–2% of the adult population over
55 years of age. For the vast majority of cases, the etiology of this disorder is unknown, although it is
generally accepted that there is a genetic susceptibility to any number of environmental agents. One such
agent may be viruses. It has been shown that numerous viruses can enter the nervous system, i.e. they are
neurotropic, and induce a number of encephalopathies. One of the secondary consequences of these
encephalopathies can be parkinsonism, that is both transient as well as permanent. One of the most
highlighted and controversial cases of viral parkinsonism is that which followed the 1918 inﬂuenza outbreak
and the subsequent induction of von Economo's encephalopathy. In this review, we discuss the neurological
sequelae of infection by inﬂuenza virus as well as that of other viruses known to induce parkinsonism
including Coxsackie, Japanese encephalitis B, St. Louis, West Nile and HIV viruses.
© 2008 Published by Elsevier B.V.The syndrome, which we know today as Parkinson's disease (PD),
wasﬁrst described in 1817byDr. JamesParkinson in a paper entitled “An
Essay on the Shaking Palsy” [1]. PD is a debilitating neurological disorder
that strikes approximately 1–2% of the adult population greater than
50 years of age [2]. Current estimates from the Parkinson's Disease
Foundation put the number of people suffering from this disease at 4.1
million people which is predicted to rise to 8.7 million based on a
projected increase in lifespan. The costs of treatment of PD can be
staggering. At an average per patient cost of $7859.00 per year (adjusted
according to the consumer price index from 1998 ﬁgures and includes
drugs, physicians and loss of pay to patient and family members), the
total cost of the disease may approach $7,800,000,000.00 per year; of
which 85% is borne to private and government (Social Security,
Medicare) insurance [3]. In fact, more individuals present with PD
thanwithmultiple sclerosis, muscular dystrophy and amyotropic lateral
sclerosis (Lou Gehrig's Disease) combined. Since PD is an incurable
diseasewith an average life expectancy after diagnosis of 15 years, there
should be an even larger burden on both the social and ﬁnancial
resources of families, insurance companies and the Federal government
in the upcoming decade than is present today.
Parkinson's disease is primarily characterized by a loss of the
pigmented cells located in the midbrain substantia nigra pars
compacta (SNpc), although cell loss has also been described in the
locus coeuleus [4], the dorsal motor nucleus of the vagus nerve [5],
and throughout the autonomic nervous system [6,7]. In addition to the
SNpc neuronal loss, there is a reduction in the number of the afferent
ﬁbers that project from this structure to the striatum. The motor1 9014953143.
eyne).
lsevier B.V.symptoms of Parkinson's disease that are themost recognizable include
the appearance of an expressionless “mask-like” face, rigidity of the
extremities also known as “cogwheeling”, bradykinesia or slowness of
movement, shufﬂing, festinating gait and lack of coordination, and a
4Hz resting tremor called “pill-rolling”. These symptoms are thought to
ﬁrst manifest when approximately 60% of the SNpc neurons have
already died [8]. In addition to these motor symptoms, there are a
number of non-motor symptoms that precede as well as follow the
onset of motor symptoms [9–11]. In addition to neuronal loss, primary
PD is also deﬁned by the presence of proteinaceous inclusion bodies
called LewyBodies. Lewybodieswereﬁrst described and linked to PDby
Frederic Lewy [12], and subsequently these have been shown to consist
of a number of proteins including aggregated alpha-synuclein [13].
The clinical presentation seen in PD can also occur in the absence
of Lewy bodies or other pathological hallmarks of primary PD [14] and
are referred to here as secondary parkinsonism. Three diseases that ﬁt
this description are Multiple System Atrophy [15], Progressive Supra-
nuclear Palsy [16] and Corticobasal Degeneration. Other causes of
secondary parkinsonism include infectious agents [17], drugs [18],
toxins [19], vascular insults [20], trauma [21], and although rare other
physiological problems such as tumor [22,23].
The underlying cause for the vast majority of PD cases is unknown.
Controversy still exists as to how much of the disease results from a
strict genetic causation, a purely environmental factor, or the more
parsimonious combination of the two risk factors [24–26]. Empirical
evidence suggests that only a small percentage (ranging from 2–10%)
of diagnosed PD has a strict familial etiology. At this time, there have
been 13 identiﬁed PD loci, including alpha-synuclein (PARK 1), parkin
(PARK2), PINK1 (PARK6), DJ-1 (PARK7) and LRRK2 (PARK8) [27].
Mutations in LRRK2 is thought to account for 1–2% of PD cases in most
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well documented kindreds [28].
The idea that viruses or other contaminating agents may be an
initiating etiology of primary PD or causative for secondary parkin-
sonism often relates to the ﬁndings of coincident cases of parkinson-
ism that lie outside of the expected. One of the most famous, and still
controversial, examples is the parkinsonism that occurred subsequent
to a viral encephalopathy that developed following the 1918 inﬂuenza
pandemic [29].
Another example that suggests viral agents can act as an initiator of
parkinsonism is the appearance of what appears to be “parkinsonian
clusters”. These are groups of individuals who share common environ-
ments and develop parkinsonism at greater than normal statistical rates
without the obvious typical risk factors. In fact, the risk factor for
developing Parkinson's disease is approximately 2X greater in people
who share close quarters, including doctors and nurses, teachers and
religion-related jobs. Several of these “parkinsonian clusters” have been
described, including those living in Israeli kibbutz's, group of college
teachers, garment workers in a manufacturing factory and a group of
actors , producers and technical staff working on a television series in
Canada [30,31].
A number of viruses have been associated with both acute and
chronic parkinsonism (see Table 1). These viruses include inﬂuenza,
Coxsackie, Japanese encephalitis B, western equine encephalitis,
herpes and those that lead to acquired immunodeﬁciency disorder
(HIV). The literature on these viruses as they relate to parkinsonism
will be reviewed.
1. Inﬂuenza virus
Neurological symptoms associated with inﬂuenza have been
reported as far back as 1385 and intermittent outbreaks with similar
symptoms have occurred at other times during inﬂuenza outbreaks
[32,33]. Inﬂuenza virus has been implicated as both a direct and
indirect cause of Parkinson's disease, based on both clinical descrip-
tions and epidemiological studies.
Inﬂuenza viruses are negative sense single-stranded RNA viruses
belonging to the family Orthomyxoviridae [34]. Inﬂuenza A viruses are
highly contagious pathogens which cause mild to severe infections in
humans. Most inﬂuenza infections, localized to the upper respiratory
tract, are self-limited lasting for about 1 week. Clinical symptoms
include acute onset of fever, myalgias, and respiratory symptoms
[35,36]. However, in severe cases, inﬂuenza infection may result in
primary viral pneumonia, secondary bacterial pneumonia or complica-
tions involving the central nervous system [37–40]. Inﬂuenza A viruses
were the etiological agent of three pandemics in the last century: the
1918 H1N1 pandemic, the 1957 H2N2 pandemic, and the 1968 H3N2
pandemic. The 1918 ﬂu pandemic, the most catastrophic pandemic,Table 1
Association of virus and parkinsonsim
Virus Family Species References
DNA Herpesviridae Herpes simplex virus [159–162]
Epstein-Barr virus [163]
Cytomegalovirus (CMV) [160,162]
Varicella zoster virus (VZV) [164]
RNA Bornaviridae Borna disease virus [165]
Orthomyxoviridae Inﬂuenza virus Type A [57,63,65,135,166–171]
Paramyxoviridae Measles [172,173]
Picornavirisae Coxsackie virus [99,100,174,175]
Echo virus [176]
Polio Virus [177]
Retroviridae Human Immunodeﬁciency
Virus (HIV)
[178–183]
Flaviviridae West Nile virus [184]
Japanese encephalitis B virus [110,166,185–192]
St. Louis Virus [92,111,193]affected large parts of theworldpopulation and is thought to have killed
at least 40million people from 1918–1919 [41]. The burden of inﬂuenza
infections during the interpandemic period continues to be an
important cause of hospitalizations, and the cumulative mortality is
greater than those associated with pandemics [42].
There is a large body of evidence that inﬂuenza can directly lead to
encephalitis [38,39,43–51]. However, the linkwith Parkinson's disease
is somewhat controversial. Much of the linkage of parkinsonism with
inﬂuenza and many other viruses stem from an outbreak of
encephalitic lethargica (EL), also known as von Economo's disease,
and the postencephalic parkinsonism that occurred subsequent to the
1918 pandemic inﬂuenza outbreak caused by a type A H1N1 inﬂuenza
virus [52]. The symptoms of EL as reported by von Economo in his
monograph Die Encephalitis Lethargica were varied. He described the
acute symptoms of 7 patients ranging in age from 14 to 32 who
presented at a psychiatric clinic in Vienna. Common to each of the
patients was somnolence, ptosis, and delerium. At the onset of the
disease the somnolence was not so severe that the patients could be
aroused and follow commands. Later in the progression of the disease,
patients would slip in and out of stupor and coma. Another common
feature was a tremor and rigidity in (generally) the upper extremities
andmost complained of nuchal rigidity. Each of these original patients
described by von Economo patients had involvement of at least 1
cranial nerve leading to paresis. Most common was the paresis of the
occulomotor nerve with associated amblyopia. He also described
paresis of the trigeminal, abducens and facial nerves. All but the 2
patients that died recovered fairly completely. Of the two patients that
died, autopsy revealed that there was meningeal involvement with
engorgement of the vessels of the brain. The autopsy also noted small
red spots that match the description of petechial hemorrhages. These
red spots were present in the cerebral cortex, medulla oblongata and
cervical spinal cord (including both the dorsal and ventral horns).
Microscopic examination showed inﬂammation of the CNS with
evenly disseminated microscopic foci in the grey matter with
preference for the midbrain. Von Economo also discussed the etiology
of what he saw and ruled out external sources such as bad sausages
(wurstvergiftung) and, because of the timing aroundWWI, poison gas
(gasvergiftung). He also ruled out meningitis and polio due to the fact
that the patients he saw had no contact with each other and each of
these was independent and no evidence of epidemics occurred as was
usually seen with these two diseases. He did discuss the possibility of
this being related to “grippe” which was another name for inﬂuenza.
Because his cases, as well as a few others (Cruchet described a similar
outbreak of “sleeping sickness” in a number of French soldiers [53]
occurred prior to the major outbreak of pandemic inﬂuenza), von
Economo ultimately concluded that what he saw was a separate
disorder from direct inﬂuenzal infection. However, he was not able to
rule out inﬂuenza as a prodromal disease.
Further studies on this disease have described 28 speciﬁc subtypes
of von Economo's encephalitis. Of these subtypes, only three will be
relevant should another inﬂuenza pandemic occur. These three
subtypes are the somnolent-opthalmoplegic type, the parkinsonian
type and the juvenile pseudopsychopathia type [54]. The second type
is most related to this review, so only it will be described. The features
of postencephalic parkinsonism both share and have distinct
symptomatology as idiopathic Parkinson's disease. Similarities
include many of the classic motor symptoms including bradykinesia,
and tremor and some parkinsonian “mask-like” features such as
ptosis, while differences can include facial twitching, myoclonus,
catatonia, mutism, the lack of Lewy bodies and the presence of
neuroﬁbrillary tangles that are common to Alzheimer's disease [54].
As discussed, the cause of EL and the link to subsequent
postencephalic parkinsonism is controversial. There is an epidemio-
logical tie, mostly based on increased incidence of PD, to the 1918
H1N1 inﬂuenza A pandemic [55–57]. For example, it has been shown
that people born during the time of the pandemic inﬂuenza outbreak
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those born prior to 1888 or after 1924 [58,59]. Pozkanzer and Schwab
[56] also showed an increase in PD onset based on an external event
occurring around 1920.
It has also been shown that several type A inﬂuenza viruses are
neurotropic, i.e. they can travel into the nervous system following
systemic infection [60–62]. Related to the ﬁnding of H1N1 neuroviru-
lence, immunoﬂuorescent staining against antigens from two type A
inﬂuenza strains have been found in the brain of a number of EL
patients, suggesting that at some time, a neurovirulent form of
inﬂuenza was present in the brain [63].
Other evidence has beenput forward suggesting that the tie toH1N1
inﬂuenza A is specious. This includes the lack of viral RNA recovered
from brains of EL and PEP patients [64], the absence of any known
mutations that would make the H1N1 virus neurotropic [52], and
questions regarding the timeline of pandemic ﬂu and EL [65]. In
addition, some recent cases of EL-like illnesseshave shown the presence
of electrophoretic oligoclonal banding in the CSF, suggesting the
presence if an immune reaction within the CNS. There has even been
some evidence that some of the cases may have a streptococcal origin
[66–68]. Recently, Kobasa et al intranasally administered the 1918H1N1
inﬂuenza virus that was generated by plasmid-based reverse genetics
[69] and found no evidence of this virus in any tissue other than lung,
heart and spleen [70]. However, theyalsonoted thatdespite thephysical
absence of the virus (based on lack of immunohistochemical detection),
that there was a robust induction of cytokines in tissues not directly
infected by the virus, including those shown to be active in long-termed
microglial responses and induction of cell death [71,72].
As suggested byVilenskywriting in a report for the Sophie Cameron
Trust (http://www.thesophiecamerontrust.org.uk/research-epe-
demic.htm), proving a negative in this case is difﬁcult. The lack of
recovery of viral RNA from EL or PEP patients is not surprising. First,
and especially in the case of PEP patients, the time from infection to
symptoms was many years and the viral infection would have been
transient. In addition, it has been shown inmanycases of encephalitis as
well as toxin induced parkinsonism the offending agent may cause a
long lasting immune response in the brain that persists many years
after the insult has resolved, leading to a “hit and run” mechanism
where the original insult is no longer present but the secondary
sequelae persists [73]. Thus, if one accepts that inﬂuenza can activate
the innate CNS immune system [74,75], one has to identify potential
second hits that could lead to development of parkinsonian symptoms.
One possible class of agents that could act as a “second hit” includes
agricultural products that were prevalent around the time of the 1918
inﬂuenza virus and the subsequent outbreak of postencephalic
parkinsonism. The ﬁrst, originally called nicouline by its discoverer
Emmanuel Geoffroy [76], and now known as rotenone, was isolated
from the roots and stems of several plants. This chemical has been used
in one form or another as a crop insecticide since 1848 and has been
recognized as a registered pesticide in the United States under the
Federal Insecticide Fungicide Rodenticide Act (FIFRA) since 1947.
Rotenone has also been found to also have properties of a pescicide
where it is generally used to rid environments of non-native predatory
ﬁsh species, such as has recently occurred on populations of the
Northern Snakehead [77]. A second pesticide that has been linked to
parkinsonism is paraquat. The herbicidal properties of the bipyridinium
compounds, including that of paraquat, were recognized in 1954 at the
Imperial Chemical Industries PLC (ICI). The ﬁrst compound to be
discovered and used was diquat dibromide but shortly afterwards in
1955, paraquat salts were discovered to be active as herbicides [78] and
were introduced to world markets around 1962 [79]. Prior to its use as
an herbicide, and as early as 1882, paraquat (also known as methyl
viologen) was synthesized by the reaction of 4,4′-bypyridium with
methyl iodide where it had been used as an oxidation-reduction
indicator [80]. Each of these chemicals induce oxidative stress and the
generation of free radicals, either through blockade of Complex I(rotenone) [81,82] or direct redox formation independent of complex I
inhibition (paraquat) [83,84]. Whatever the cause of increased
oxidative stress, it is clear that prior activation of microglia increases
sensitivity to these agents [85,86]. As noted earlier, it is well established
that inﬂuenza can induce microglial activation in the CNS [74].
Despite the controversy regarding the linkage of EL and the 1918
inﬂuenza virus- and as stated above- it has been shown that certain
strains of inﬂuenza are neurotropic in mammals. Takahashi et al have
shown that one inﬂuenza A virus (A/WSN/33 (H1N1)) preferentially
targets the substantia nigra and ventral tegmental area prior to its
spread throughout the CNS [87]. In a similar fashion, the highly
pathogenic H5N1 inﬂuenza virus, which currently has pandemic
potential, has been shown to be neurotropic [60,88,89]. According to
theWHO, this strain of inﬂuenza A, H5N1 subtype has spread through
the Eurasian avian population and has infected at least 350 humans, of
which more than 50% have died. Following infection with H5N1,
animal populations infected with H5N1 demonstrate clear motor
effects that include abnormal postures, difﬁculties in maintaining an
upright posture, and the inability to initiate movement. The onset of
post-inﬂuenzal encephalopathies are not limited to animals as there is
one case report of humans exposed to H5N1 – a 4-year-old and his 9-
year-old sister – both of whom presented with rapid encephalopathy
followed by coma and death [45]; its rapid course and lack of
resources did not allow MRI studies to be performed. In addition to
this one published case report, there are other reports of post H5N1
inﬂuenza infection encephalitis including a 67-year-old woman from
Indonesia's West Java province who in addition to her severe
respiratory symptoms developed encephalitis [90].
1.1. Other viruses associated with postencephalic parkinsonsim
Although rare, there have been many case reports of non-
traditional secondary parkinsonism subsequent to viral infection. An
excellent compendium of historical cases has been reviewed by Casals
et al [65] (also see Table 1). In the following section, we will review
literature on some of the more common viruses associated with
secondary parkinsonism including coxsackie virus, Japanese encepha-
litis B, St. Louis and West Nile, and HIV. While each of these viruses
have been shown to induce some of the cardinal motor symptoms of
PD, and some are treatable by L-DOPA therapy [91,92], none have been
reported to induce Lewy body formation and as such only phenocopy
the disease symptoms.
1.2. Coxsackie virus
Coxsackie virus was ﬁrst isolated from human feces in the town of
Coxsackie, New York, in 1948 by Gilbert Dalldorf and Grace Sickles
[93,94]. Coxsackie virus is a member of the Picornaviridae family of
viruses in the genus termed Enterovirus. According to the Center for
Disease Prevention and Control, there are 66 serotypes of enterovirus'
and these include 3 polioviruses. Coxsackie viruses are RNA viruses
that primarily affect children and young adults [95]. Infection with
Coxsakie virus can easily be passed from person to person and been
associated with a number of diseases, including meningitis [96],
myocarditis [97], and pericarditis [98].
Acute parkinsonism has been noted after infection with Coxsackie
virus [99,100] although its association with traditional aged-onset
idiopathic Parkinson's disease has never been established. As with
inﬂuenza virus, it is possible that early infection with Coxsackie virus
can induce a long lived activation with glial cells that would
predispose to oxidative insult much later in life [101].
1.3. Japanese encephalitis B, St. Louis and West Nile viruses
Japanese encephalitis B (JEBV), St. Louis and West Nile viruses are
single-stranded RNA viruses that are transmitted by the bite of
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viruses are often resolved prior to any CNS involvement, on rare
occasion, these viruses can lead to encephalitis [105]. In fact, JEBV is
the most common cause of encephalitis in Asia [106]. If infection does
involve the CNS, the regions of the brain noted to become involved
include the thalamus, basal ganglia, brain stem, cerebellum, hippo-
campus, and cerebral cortex [107–109].
Ogata et al experimentally infected Fisher rats with JEBV and noted
a marked gliosis in the SNpc, in a pattern typical of the lesion seen in
Parkinson's disease [110], Behaviorally, the rats exhibited bradykinesia
that was reversed with administration of L-DOPA and a MAO inhibitor
suggesting that the virus had the ability to directly induce one of the
cardinal symptoms of Parkinson's disease.
Secondary Parkinson's disease subsequent to St. Louis encephalitis
has also been described. Like JEBV, this virus primarily affects children
and the aged, although numerous cases of infection and secondary
parkinsonism has been reported in all age groups. Pranzatelli et al
report a number of cases of secondary parkinsonism in children, one of
which appear to be the result of active St. Louis encephalopathy [92]. In
this case, the patient had features of moderate parkinsonism (a UPDRS
score of 92 and a MHYS of 5) with a predominant symptom of
dysphagia and dystonic posture. The parkinsonism symptoms did not
progress and resolved after a few months. During the clinical course of
the parkinsonism, MRI reveled a slight enhancement of the basal
ganglion. In the adult cases, each patient presentedwith involvement of
the substantia nigra as determined byMRI [111]. The ﬁrst patient was a
21-year-old male who presented with a 1-week history of fever and
headache. Neurologic examination was normal, and an admitting
diagnosis of aseptic meningitis was made. The symptoms progressed
with new symptoms of fever, ataxia, nystagmus, and tremulousness.
MRI imaging revealed a T2-weighted bilateral hyperintensity in the
substantia nigra without enhancement. In a second case, a 37-year-old
male with a history of paranoid schizophrenia and seizures presented
with fever and confusion and was generally unresponsive to
commands. Other symptoms included nuchal rigidity diffuse, general-
ized hypertonicity, and abnormal postures including ﬂexed upper
extremities, a bilateral Babinski response and an absent gag reﬂex. Like
the previous patient, MRI imaging showed an asymmetric T2-weighted
non-enhanceable hyperintensity in the substantia nigra. Similar lesions
have been reported in other cases of St. Louis encephalopathies.
1.4. HIV
Human immunodeﬁciency virus (HIV, originally called HTLV) is a
retrovirus that has been shown to be the cause of acquired
immunodeﬁciency syndrome (AIDS) [112]. Infection with HIV results
in a failure of the immune system, leading to life-threatening
opportunistic infections. The underlying cellular lesion in HIV is a
progressive loss of CD4+ T cells whose levels correlate with the viral
load. In addition to the loss of the peripheral immune system, one of
the most common associated pathologies from HIV infection involves
motor disturbances [113,114]. The involvement of the CNS can occur
quickly since HIV has been detected in the brainwithin 2 weeks of the
initial infection [115]. Once in the brain, HIV has been clearly shown to
infect astrocytes and microglia [116–118]. In addition, and although
controversial, there is also some evidence that HIV can also directly
infect neurons [119–121]. Nomatter where the infection, the presence
of the virus has been shown to induce a cytokine “storm” [122,123].
Depending on the size of the study cohorts, it has been estimated
that from 5–50% of all AIDS patients suffer from some sort of motor
dysregulation including those seen in Parkinson's disease such as
bradykinesia, cogwheel rigidity and tremor [114]. These movement
disorders result from both primary HIV infection and secondary
opportunistic infections. Primary HIV-associated parkinsonism often
appears within several months of the diagnosis of HIV infection [113]
and its appearance portends a poor prognosis. Cerebral imaging (CTand MRI) of HIV-induced parkinsonism has shown lesions at various
levels of the basal ganglia including calciﬁcations throughout the basal
ganglia, hypodense lesions of the striatum [124], putamen hyper-
trophy [125,126] as well as intensifying lesions of the basal ganglia
[127,128] and midbrain [129]. Functional imaging using [18F] ﬂuor-
odeoxyglucose PET have shown that early CNS changes in AIDS
involved thalamic and basal ganglia hypermetabolism while cortical
and subcortical gray matter hypometabolism was more characteristic
of later CNS changes [130].
2. Viral neurotropism
If one is to understand the neurological pathogenesis of viruses,
understanding how they enter into the nervous system is of critical
importance. A number of viruses, including obviously the viruses
described in this manuscript have the ability to enter the CNS.
Although the phenomenon is well described, the mechanism towhich
this occurs has not been deﬁned. Most of the work on neurotropism
has been done using the inﬂuenza virus as an experimentalmodel. In a
study examining neurovirulance in mice, Lipatov et al [89] examined 5
H5N1 inﬂuenza viruses isolated in Hong Kong in 2001 of which 4were
neurotropic (Ck/HK/YU822.2/01, Ph/HK/FY155/01, Ck/HK/FY150/
01, Ck/HK/NT873.3/01) and 1 was not (Ck/HK/YU562/01). This
group did extensive sequence analysis of these viruses and found that
there was not a common set of mutations that induced neurotropism,
suggesting the neurovirulence of the inﬂuenza virus is a polygenic
trait. They found that multiple basic cleavage sites in the surface
hemagglutinin proteins were necessary, but not sufﬁcient, to make
these viruses neurovirulent. In addition, they also suggested that
speciﬁc changes in polymerase proteins PB2 and PA, which are
important in transcription and replication of viral RNAs [131], are also
implicated in this process. In addition, several studies have found that
mutations in the Mx gene, which regulate GTPase activity [132,133],
and act as an important downstream effector of interferon [134], also
regulate Type A inﬂuenza neurotropism. MxA protein has also been
found to be a component of Lewy Bodies [135–137] and therefore may
link inﬂuenza to parkinsonism. As an aside, one treatment for
inﬂuenza, Amantadine which targets the M2 protein channel on the
surface of the inﬂuenza A virus [138,139], has also been used as a
limited treatment for Parkinson's disease [140,141].
In terms of how inﬂuenza virus enters the CNS, the A/WSN/33
strain has been shown to enter the CNS via the olfactory epithelium
[142]. It has also been hypothesized that it can enter the CNS via other
cranial nerves including the vagus and trigeminal nerves [143–146].
These three nerves have processes that innervate visceral organs and
tissues that would be ﬁrst contacted by intranasal viral infection
including the olfactory epithelium (olfactory nerve, CN I), orofacial
mucosa (trigeminal nerve, CN III) and digestive system (vagus nerve,
CN X). The basis of this hypothesis – which does not have any direct
proof such as isolation of the virus from axons of these nerves – is two-
fold. First, examination of the CNS following infection via intranasal
routes shows that the virus is ﬁrst seen in the regions innervated by
these nerves. Second, the virus can be detected (indirectly by the
presence of immunohistochemical detection of viral nuclear protein,
anti-NP) in the visceral ganglia [88,146]. One argument against this
route of entry into the CNS is that the A/WSN/33 strain of inﬂuenza
has afﬁnity for the substantia nigra [87], a neuronal population
without any direct anatomical connection to the cranial nerve system.
This suggests that inﬂuenza virus may also enter into the CNS via
different mechanisms than axonal transport such as through the
ependymal cells lining the ventricles and shedding into the CSF where
it can freely transmit through the whole neuraxis, through the blood
and extravasation from penetrating capillaries in the brain or invasion
into the CNS via reductions in the blood-brain-barrier around the
circumventricular organs. Braak [147] suggests Parkinson's disease
may be caused by an infectious agent based on the location of Lewy
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olfactory bulb and gastrointestinal enteric plexi such as Meissner's
plexus ultimately reaching preganglionic parasympathetic motor
neurones of the vagus nerve. They call this dual route for entry into
the brain of an unknown pathogen a 'dual-hit' hypothesis.
While many studies have been done examining the genetics of the
viruses and how they inﬂuence neurotropism, little has been done to
explore the host genetics in terms of resistance to neurotropism [148].
One method for identifying these inherent genetic factors, in the
absence of any speciﬁc genes to examine, is the use of quantitative trait
loci analysis [149,150]. The premise behind QTL analysis is that if
numerous geneticmarkers are examined, only those that segregatewith
a particular phenotype will contain the gene(s) that underlie the trait
being examined [151]. QTL analysis in mice has been facilitated in the
last 10 years by several signiﬁcant advances. First, thousands of
microsatellite markers have been found and mapped to their speciﬁc
chromosomal region spanning the entire murine genome [152].
This method can identify regions of chromosomes responsible for
differences in any measurable trait and has been used to identify genes
responsible for susceptibility to a number of neurological phenomenon
[149,153–155] and could easily be used to identify chromosomal regions
of interest and ultimately genes that regulate neurotropism sensitivity
in the host animal (if they exist). The identiﬁcation of these genes
could have a signiﬁcant impact on public health in the event of
pandemic ﬂu.
Based on all available evidence, we suggest that viruses, and in
particular inﬂuenza virus, can be one precipitating factor in the
development of Parkinson's disease. Although there is little evidence
suggesting that infection by any virus directly induces Parkinson's
disease (although there might be some transient parkinsonism
associated with direct encephalitis), it is clear that some inﬂuenza
viruses can both enter the CNS and cause cell death, but more
importantly they have been shown to induce a cytokine storm in the
brain. The sequelae of cytokine induction, such as activation of
microglia, can be long lasting and far exceed the presence of the
initiating factor. Further support for this hypothesis is the pattern of
viral protein expression in the brain of animals and humans exposed to
some inﬂuenza viruses [63,87,156,157] that mimics those identiﬁed by
Braak as regions of disease during early pathogenesis [158].We suggest
that infectious agentsmay be the ﬁrst “hit” in a two hit hypothesis, and
that this insult sensitizes the brain to a later “hit” that might not have
been pathogenic in the absence of an already primed system.References
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